PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

(2012) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

(2011) O A Khan et al.   BRITISH JOURNAL OF CANCER

CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle

(2011) P. Dent et al.   MOLECULAR INTERVENTIONS

PARP inhibitors stumble in breast cancer

(2011) Malini Guha   NATURE BIOTECHNOLOGY

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

(2010) C. Mitchell et al.   MOLECULAR PHARMACOLOGY

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

(2010) C. E. Strom et al.   NUCLEIC ACIDS RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Development of PARP inhibitors in oncology

(2008) Jordi Rodon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

(2008) H. Hamed et al.   MOLECULAR CANCER THERAPEUTICS

Early events in the mammalian response to DNA double-strand breaks

(2008) L. C. Riches et al.   MUTAGENESIS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE